Donald L. Siegel, MD, PhD

faculty photo
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Department: Pathology and Laboratory Medicine

Contact information
9-112 South Tower, Big 421
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: (215) 662-3942
Lab: (215) 898-9655
Education:
Sc.B. (Biophysics)
Brown University, 1977.
Ph.D. (Biophysics)
Harvard University, 1983.
M.D.
University of Pennsylvania, 1987.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Research Interests

Discovery and characterization of diagnostic and therapeutic monoclonal antibodies

Research Summary

My laboratory studies human immune repertoires in health and disease using phage display technologies for the production of human and non-human monoclonal antibodies relevant to transfusion medicine, benign hematology, infectious diseases, and oncology. Current studies focus on developing targeted drug delivery methods using red cell antibodies coupled to novel anti-thrombotic/anti-inflammatory molecules; cloning monoclonal primate neutralizing Dengue, Ebola, MERS and Zika virus antibodies for human in vivo antibody gene expression therapy; and isolating recombinant human and humanized antibody fragments for the design of T-cell chimeric antigen receptors for cancer therapy.

Description of Clinical Expertise

transfusion medicine, blood banking, apheresis, hematopoietic stem cell collection/processing, cGMP manufacture of cellular therapies for phase I first-in-human clinical trials

Selected Publications

Cohen, A., Garfall, A, Stadtmauer, E., Melenhorst, J., Lacey, S., Lancaster, E., Vogl, D., Weiss, B., Dengel, K., Nelson, A. M., Plesa, G., Chen, F., Davis, M., Hwang, W.-T., Young, R., Brogdon, J., Isaacs, R., Pruteanu-Malinici, I., Siegel, D. L., Levine, B., June, C. H., Milone, M.C.: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest 129: 2210-2221, 2019.

Ozerova, M., Xu, J., Pequignot, E.C., McKee, J.S., Gohil, M., Haines, K., Lamontagne, A.M., Siegel, D.L., Levine, B.L., Davis, M.M.: Evaluation of cryopreservation media formulation for collected leukapheresis products and for final manufactured T-cell products. 2019 ISCT Regional Meeting, Madison, WI 2019.

Gutjahr, A., Heck, F., Emtenani, S., Hammers, A.-K., Hundt, J.E., Muck, P., Siegel, D.L., Schmidt, E., Stanley, J.R., Zillikens, D., Hammers, C.M., Brit J Dermatol: Bullous pemphigoid autoantibody-mediated complement fixation is abolished by the low molecular-weight heparin tinzapatin sodium. Brit J Dermatol 181: 593-594, 2019.

Choi, H., Kudchodkar, S.B., Reuschel, E.L., Asija, K., Borole, P., Agarwal, S., Van Gorder, L., Reed, C.C., Gulendram, G., Ramos, S., Broderick, K.E., Kim, J.J., Ugen, K.E., Kobinger, G., Siegel, D.L., Weiner, D.B., Muthumani, K.: Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge. Human Vaccines & Immunotherapeutics in press, 2019.

Chong, E.A., Levine, B.L., Gruppp, S.A., Davis, M.M., Siegel, D.L., Maude, S.L., Gladney, W.L., Frey, N.V., Porter, D.L., Hwang, W.-T., Chong, E.R., June, C.H., Schuster, S.J.: CAR T cell viability release testing and clinical outcomes: is there a lower limit? Blood in press, 2019.

Garfall, A.L., Dancy, E., Cohen, A.D., Hwang, W.-T., Fraietta, J., Davis, M.M., Levine, B.L., Siegel, D.L., Stradtmauer, E., Vogl, D.T., Waxman, A., Rapoport, A.P., Milone, M., June, C.H., Melenhorst, J.J.: T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma. Blood Advances 3: 2812-2815, 2019.

Chong, E.A., Gerson, J.N., Landsburg, D.J., Nasta, S.D., Svoboda, J., Porter, D.L., Dengel, K., Gilmore, J., Siegel, D., Barta, S., Levine, B.L., June, C.H., Schuster, S.J.: Outcomes in aggressive B-cell non-Hodgkin lymphomas with anti-CD19 CAR T-cell (CTL019) products not meeting commercial release specifications. Blood in press, 2019.

Gohill M., Dai A., Mackey S., Negorev D., Hennesy N., O’Rourke M., Lamontagne A., Holland D., Leskowitz R.M., Xu J., Ozerova M., McKee J.S., Pequignot E., Siegel D.L., Schuster S., Svoboda J., Garfall A., Cohen A., Stadtmauer E., Gladney W., Levine B.L., June C., Fraietta J.A., Davis M.M.: Myeloid derived suppressor cells (MDSCs) reduce the manufacturing feasibility of gene-edited T cells. 2019 Meeting of the International Society for Cellular Therapy, Melbourne, Australia 2019.

Gladney W.L., Leskowitz R., Dai A., McKee J., Gohil M., Xu J., Davis M., O’Rourke M., Siegel D., Lacey S.F., Marshall A., Veloso E., Hwang W.-T., Hexner E., Porter D., Frey N., June C.H.: A systematic approach to developing an allogeneic CAR T cell product. CAR-T and the rise of Cellicon Valley, Philadelphia, PA 2019.

Nobles, C., Sherrill-Mix, S., Everett, J.K., Reddy, S., Fraietta, J., Porter, D., Frey, N., Gill, S.I., Grupp, S., Maude, S., Siegel, D.L., Levine, B.L. June, C.H., Lacey, S., Melenhorst, J., Bushman, F.: Linking CART19 immunotherapy outcome with genomic modification by vector integration. J Clin Invest in press, 2019.

back to top
Last updated: 12/10/2019
The Trustees of the University of Pennsylvania